CFD wind-driven rain simulations and their use for HAM modeling

Wind-driven rain is one of the most important boundary conditions for numerical Heat-Air-Moisture (HAM) transfer models. Due to the complexity of WDR however, the current HAM models generally incorporate it in a very simplified way. Recent research has shown that CFD can provide accurate estimates of WDR on building facades. Therefore, in this paper, a combined CFD-HAM approach is presented. It is applied for a simplified wall model. It is shown that the accuracy of the HAM-simulation results is to a large extent determined by the time resolution of the meteorological input data and by the data-averaging technique used for these data. Some guidelines for accurate HAM analyses with WDR are provided

Local wind speed near exterior building surfaces for convective transfer coefficients

Exterior convective heat and mass transfer coefficients at building surfaces are to a large extent determined by the local wind speed. Usually, empirical formulae are used to relate the reference wind speed at a meteorological station to the local wind speed near the building surface and to relate the local wind speed to surface transfer coefficients. These formulae however are based on a limited number of measurements. Little is known about the actual value and the variability of local wind speed and surface transfer coefficients across facades of different building geometries. In this paper, a validated Computational Fluid Dynamics (CFD) model is used to calculate the local wind speed near the exterior surface of a cubic building model as a function of wind speed, wind direction and the position on the facade. It is shown that the variation of the local wind speed across the facade is very pronounced and that using the available empirical formulae can yield large errors in HAM (Heat-Air-Moisture) calculations

National context as a predictor of high-performance work system effectiveness in small-to-medium-sized enterprises (SMEs): a UK–French comparative analysis

High-performance work systems (HPWSs), a large firm model, have recently attracted interest within small-to-medium-sized enterprises (SMEs). In addition, institutional settings have been shown as an important determinant in the types of human resource management (HRM) practices adopted by employers. This paper progresses these topics through a comparative analysis of SMEs within Cote d’Opale/Nord Pas de Calais (French) and Kent (UK) regions. Clear divergence is evident in the nature of HPWS. Whilst UK SMEs are found to adopt a wider range of practices, French firms exhibit a higher degree of integration portrayed through a collective range of practices that engender employee participation and commitment

Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review

At least 25 – 30% of patients with cancer and an even higher percentage of patients in an advanced phase of illness meet the criteria for a psychiatric diagnosis, including depression, anxiety, stress-related syndromes, adjustment disorders, sleep disorders and delirium. A number of studies have accumulated over the last 35 years on the use of psychotropic drugs as a pillar in the treatment of psychiatric disorders. Major advances in psycho-oncology research have also shown the effi cacy of psychotropic drugs as adjuvant treatment of cancer-related symptoms, such as pain, hot fl ushes, pruritus, nausea and vomiting, fatigue, and cognitive impairment. The knowledge about pharmacokinetics and pharmacodynamics, clinical use, safety, side effects and effi cacy of psychotropic drugs in cancer care is essential for an integrated and multidimensional approach to patients treated in different settings, including community-based centres, oncology, and palliative care. A search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) was conducted in order to summarize relevant data concerning the effi cacy and safet

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. Patients were followed for 1 to 3 years. FINDINGS: 19,185 patients, with more than 6300 in each of the clinical subgroups, were recruited over 3 years, with a mean follow-up of 1.91 years. There were 1960 first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5.32% risk of ischaemic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin. These rates reflect a statistically significant (p = 0.043) relative-risk reduction of 8.7% in favour of clopidogrel (95% Cl 0.3-16.5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9.4%. There were no major differences in terms of safety. Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash (0.26% vs 0.10%), diarrhoea (0.23% vs 0.11%), upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial haemorrhage (0.33% vs 0.47%), and gastrointestinal haemorrhage (0.52% vs 0.72%), respectively. There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L) and 16 (0.17%) in the aspirin group. INTERPRETATION: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin